Pulmonary Vasodilation
Pulmonary Vasodilation - Related Videos
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
0 Views •
Cited by 165 •
2010
A noninvasive procedure to assess endothelial function is demonstrated using the Endo-PAT 2000.
08:09
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
0 Views •
Cited by 1 •
2017
We describe the isolation of cardiac extracellular matrix from C57Bl/6J control mice, tight-skin mice, and tight-skin mice treated with the IRF5 inhibitory peptide. We also describe the vasodilation studies on the isolated vessels from C57Bl/6J, tight-skin mice and tight-skin mice treated with the IRF5 inhibitory peptide.
01:23
Antihypertensive Drugs: Vasodilators
0 Views •
2024
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
08:17
Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
0 Views •
Cited by 8 •
2017
The following protocol describes the methodology for the acquisition and analysis of echocardiographic images used to obtain the Left Atrial Volume (LAV), Aorta (Ao) diameter, and Pulmonary Artery (PA) diameter in mice. This technique is a non-invasive, non-terminal procedure that allows assessment of the cardiopulmonary function.
06:59
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
0 Views •
2025
Pulmonary vein stenosis (PVS) is a life-threatening complication of fibrosing mediastinitis (FM), with a poor prognosis if not properly treated. Currently, catheter-based endovascular angioplasty is a promising therapeutic strategy for FM-associated PVS. This protocol primarily outlines a stepwise approach to the transcatheter procedure for FM-associated PVS.
FAQs
Pulmonary arterial smooth muscle can relax through several intracellular signaling routes. Nitric oxide promotes cyclic guanosine monophosphate signaling, whereas prostacyclin analogs engage cyclic adenosine monophosphate signaling. These pathways reduce vascular tone, lower resistance in the pulmonary circulation, and provide distinct pharmacological entry points for treating pulmonary hypertension.
Reduced intracellular calcium provides a separate mechanism for relaxing pulmonary arterial smooth muscle. Because calcium is presented in the source as a key intracellular factor, its reduction represents a signaling condition associated with vessel widening and decreased pulmonary vascular resistance. This route complements messenger-based pathways involving cyclic guanosine monophosphate and cyclic adenosine monophosphate.
Therapeutic benefit depends not only on widening pulmonary vessels but also on limiting unwanted systemic effects. The pharmacological goal is to reduce pulmonary vascular resistance while minimizing a fall in systemic blood pressure and preserving ventilation-perfusion matching, the relationship between air reaching the lungs and blood flowing through them. These considerations guide targeted treatment.
They represent different pharmacological options for influencing the pulmonary circulation. Inhaled nitric oxide is linked to the nitric oxide and cyclic guanosine monophosphate pathway, while prostacyclin analogs are linked to cyclic adenosine monophosphate signaling. Phosphodiesterase-5 inhibitors form a third drug class used in this setting. Their shared clinical purpose is pulmonary vasodilation.
In the provided pharmacological context, these therapies are used for pulmonary hypertension, a condition in which controlling pulmonary vascular resistance is clinically important. Lower resistance can help regulate blood flow through the pulmonary circulation and improve right-heart function. The choice of inhaled nitric oxide, prostacyclin analogs, or a phosphodiesterase-5 inhibitor reflects targeted treatment within this therapeutic setting.
Improved right-heart function is a relevant outcome because the right side of the heart pumps blood through the pulmonary circulation. By lowering pulmonary vascular resistance, pulmonary vasodilation can reduce the vascular resistance encountered in that circulation and support more effective flow. In pharmacology, this outcome helps connect molecular smooth-muscle signaling with clinical treatment goals.